Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats

Journal of Molecular Histology

Volumn 40, Issue 4, 2009, Pages 317-324

  Paiotti, Ana Paula Ribeiro ^a   Miszputen, Sender Jankiel ^a   Oshima, Celina Tizuko Fujiyama ^a   De Oliveira Costa, Henrique ^a   Ribeiro, Daniel Araki ^a   Franco, Marcello ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclooxygenase 2; Inflammatory bowel disease; Lumiracoxib; QRT PCR; TNBS colitis

Indexed keywords

CYCLOOXYGENASE 2; LUMIRACOXIB; MESSENGER RNA; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME;

ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; RATS; RATS, WISTAR; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID;

RATTUS; RATTUS NORVEGICUS;

EID: 72349099110     PISSN: 15672379     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10735-009-9243-0     Document Type: Article

References (34)

1. D Barbieri 2000 Inflammatory bowel diseases J Pediatr (Rio J) 76 S173 S180
2. DK Bonen JH Cho 2003 The genetics of inflammatory bowel disease Gastroenterology 124 521 536 10.1053/gast.2003.50045 1:CAS:528: DC%2BD3sXhsFOgs78%3D 12557156 (Pubitemid 36169267)
3. K Brune B Hinz 2004 Selective cyclooxygenase-2 inhibitors: similarities and differences Scand J Rheumatol 33 1 6 1:CAS:528:DC%2BD2cXhtVajtr%2FJ 15124935
4. S Colpaert Z Liu B De Greef P Rutgeerts JL Ceuppens K Geboes 2001 Effects of anti-tumour necrosis factor, interleukin-10 and antibiotic therapy in the indometacin-induced bowel inflammation rat model Aliment Pharmacol Ther 15 1827 1836 10.1046/j.1365-2036.2001.01111.x 1:CAS:528:DC%2BD3MXosVWqtLs%3D 11683697 (Pubitemid 33001147)
5. S Cuzzocrea E Mazzon I Serraino L Dugol T Centorrino A Ciccolo L Sautebin AP Caputi 2001 Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulphonic acid in rats Eur J Pharmacol 431 91 102 10.1016/S0014-2999(01)01403-0 1:CAS:528:DC%2BD3MXosFOjt7s%3D 11716847 (Pubitemid 33082156)
6. W Dempke C Rie A Grothey HJ Schmoll 2001 Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127 411 417 10.1007/s004320000225 1:CAS:528:DC%2BD3MXktFWgsrY%3D 11469677 (Pubitemid 32524357)
7. A El-Medany A Mahgoub A Mustafa M Arafa M Morsi 2005 The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats Eur J Pharmacol 507 291 299 10.1016/j.ejphar.2004.11.036 1:CAS:528:DC%2BD2MXkvVCgtg%3D%3D 15659320 (Pubitemid 40126866)
8. CO Élson RB Sartor GS Tennyson RH Riddell 1995 Experimental models of inflammatory bowel disease Gastroenterology 109 1344 1367 10.1016/0016-5085(95)90599-5 7557106
9. R Esser C Berry Z Du J Dawson A Fox RA Fujimoto W Haston EF Kimble J Koehler J Peppard E Quadros J Quintavalla K Toscano L Urban J Van Duzer X Zhang S Zhou PJ Marshall 2005 Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 Br J Pharmacol 144 538 550 10.1038/sj.bjp.0706078 1:CAS:528:DC%2BD2MXhsVOmsbk%3D 15655513 (Pubitemid 40349461)
10. L Feng W Sun Y Xia WW Tang P Chanmugam E Soyoola CB Wilson D Hwang 1993 Cloning two isoforms of rats cyclooxygenase: differential regulation of their expression Arch Biochem Biophys 307 361 368 10.1006/abbi.1993.1601 1:CAS:528:DyaK2cXhtVSns70%3D 8274023
11. F Halter AS Tarnawski A Schmassmann BM Peskar 2001 Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives Gut 49 443 453 10.1136/gut.49.3.443 1:CAS:528:DC%2BD3MXnt1Cqu78%3D 11511570 (Pubitemid 32802583)
12. CJ Hawkey P Svoboda IF Fiedorowicz-Fabrycy EL Nasonov EG Pikhlak M Cousin X Gitton G Hoexter 2004 Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis J Rheum 31 1804 1810 1:CAS:528:DC%2BD2cXosVKls7o%3D 15338504
13. H Jiang CH Deng M Zhang J Xia 2006 Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2 World J Gastroenterol 12 3848 3853 1:CAS:528: DC%2BD28Xot1Kit70%3D 16804969
14. S Kargman S Charlesion M Cartwright J Frank D Riendeaw J Mancini J Evans G O'Neill 1996 Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts Gastroenterology 111 445 454 10.1053/gast.1996.v111.pm8690211 1:CAS:528:DyaK28XkvFOnsbw%3D 8690211 (Pubitemid 26256734)
15. AJ Kivitz S Nayiager T Schimansky A Gimona HJ Thurston C Hawkey 2004 Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis Aliment Pharmacol Ther 19 1189 1198 10.1111/j.1365-2036.2004.01956.x 1:CAS:528:DC%2BD2cXlsFyiurk%3D 15153172 (Pubitemid 38746262)
16. BA Lashner 1995 Epidemiology of inflammatory bowel disease Gastroenterol Clin North Am 24 467 474 1:STN:280:DyaK28vgsFSqsw%3D%3D 8809231
17. DR Lichtenstein MM Wolfe 2000 COX-2 selective NSAIDS. New and improved? J Am Med Assoc 284 1297 1299 10.1001/jama.284.10.1297 1:STN:280: DC%2BD3cvjvVGquw%3D%3D
18. U Mahadevan EV Loftus WJ Tremaine 2001 Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease Am J Gastroenterol 97 910 914 10.1111/j.1572-0241.2002.05608.x
19. JB Mangold H Gu LC Rodriguez J Bonner J Dickson C Rordorf 2004 Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects Drug Metab Dispos 32 566 571 10.1124/dmd.32.5.566 1:CAS:528:DC%2BD2cXjs1Grsbo%3D 15100180 (Pubitemid 38535036)
20. AR Martin I Villegas C La-Casa C Alarcon de la Lastra 2003 The cyclooxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats Eur J Pharmacol 481 1 10 10.1016/j.ejphar.2003.09.033 (Pubitemid 37464980)
21. H Mizuno T Akamatsu M Kasuga 1997 Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice Gastroenterology 112 387 397 10.1053/gast.1997.v112.pm9024292 1:CAS:528:DyaK2sXhsVKht7g%3D 9024292 (Pubitemid 27078825)
22. GP Morris PL Beck MS Herridge WT Depew MR Szewczuk JL Wallace 1989 Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 96 795 803 1:STN:280:DyaL1M7itFeqtQ%3D%3D 2914642
23. GP O′Neill AW Ford-Hutchinson 1993 Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues FEBS Lett 330 156 160 8365485
24. M Okayama S Hayashi Y Aoi H Nishio S Kato K Takeuchi 2007 Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats Dig Dis Sci 52 2095 2103 10.1007/s10620-006-9597-z 1:CAS:528:DC%2BD2sXoslGisro%3D 17429720 (Pubitemid 47246503)
25. DK Podolsky 2002 Inflammatory bowel disease N Engl J Med 347 417 429 10.1056/NEJMra020831 1:CAS:528:DC%2BD38XlvFKrt7s%3D 12167685 (Pubitemid 34851835)
26. BK Reuter S Asfaha A Buret, et al. 1996 Exacerbation of inflammatory associated colonic injury in rat through inhibition of cyclooxygenase-2 J Clin Invest 98 2076 2085 10.1172/JCI119013 1:CAS:528:DyaK28XmvVequrY%3D 8903327
27. C Rordorf N Kellett S Mair, et al. 2003 Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects Aliment Pharmacol Ther 18 533 541 10.1046/j.1365-2036.2003.01691.x 1:CAS:528:DC%2BD3sXot1Oqt7c%3D 12950426 (Pubitemid 37152294)
28. J Shigeta S Takahashi S Okabe 1998 Role of cyclooxygenase-2 in the healing of gastric ulcers in rats J Pharmacol Exp Ther 286 1383 1390 1:CAS:528:DyaK1cXmt1GqsL4%3D 9732401
29. RG Shorter KA Huizenga RJ Spencer SK Guy 1972 Inflammatory bowel disease. The role of lymphotoxin in the cytotoxicity of lymphocytes for colonic epithelial cells Am J Dig Dis 17 689 696 10.1007/BF02231636 1:STN:280: DyaE383ktFSjtw%3D%3D 5046733
30. II Singer DW Kawka S Schloemann T Tessner T Riehl WF Stenson 1998 Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease Gastroenterology 115 297 306 10.1016/S0016-5085(98)70196-9 1:CAS:528:DyaK1cXltl2nsr0%3D 9679035 (Pubitemid 28363422)
31. S Somasundaram S Rafi J Hayllar G Sigthorsson M Jacob AB Price A Macpherson T Mahmod D Scott JM Wrigglesworth I Bjarnason 1997 Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine Gut 41 344 353 1:CAS:528:DyaK2sXms1Shs78%3D 9378390
32. P Suenaert V Bulteel S Vermeire M Noman G Van Assche P Rutgeerts 2005 Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent Inflamm Bowel Dis 11 667 673 10.1097/01.MIB. 0000168371.87283.4b 15973122 (Pubitemid 40961081)
33. H Ukawa H Yamakuni S Kato K Takeuchi 1998 Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs on gastric ulcerogenic and healing responses in experimental animals Dig Dis Sci 43 2003 2011 10.1023/A:1018846912032 1:CAS:528:DyaK1cXmsV2rsrw%3D 9753266 (Pubitemid 28436218)
34. L Zhang YM Lu XY Dong 2004 Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid Chin J Dig Dis 5 110 114 10.1111/j.1443-9573.2004.00164.x 1:CAS:528: DC%2BD2cXns1Kjs7Y%3D 15612245 (Pubitemid 39199625)